MegatrendsMegatrends: not the usual suspects, but who actually profits.View megatrends →

Pfizer Stock

Pfizer Inc.

PFENYSERadar
US$29.58
+0.5% today

Company data

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
CEO
Albert Bourla
Employees
75,000
Market cap
$168.6 B
IPO
01/06/1972

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Headquartered in New York City, USA, the company was established in 1849. Its comprehensive portfolio addresses diverse therapeutic…

Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.

Pfizer stock: price history

16/10/25+22.1 %16/10/26

1D

+0.5%

1W

+4.6%

1M

+7.7%

6M

+7.3%

YTD

+18.8%

1Y

+22.1%

2Y

-0.3%

5Y

-28.7%

10Y

-4.5%

Next earnings date

Next earnings date

03/11/2026 (in 17 days)

Volatility around earnings

~24% stronger price swings than usual

Pattern chart

Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta

What does this mean?

Double bottom

Bullish

The price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.

Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.

Pfizer stock scores

  • Valuation

    Visible after free registration

  • Trend

    Visible after free registration

  • Quality

    Visible after free registration

  • Dividend

    Visible after free registration

  • Growth

    Visible after free registration

  • Insider

    Visible after free registration

  • Earnings

    Visible after free registration

  • Revisions

    Visible after free registration

  • Sentiment

    Visible after free registration

  • Short Pressure

    Visible after free registration

Register for free

Unlock all 11 scores

  • 5 credits free on registration
  • Access to virtual portfolios and watchlist
  • No credit card, no payment details needed
  • No subscription, no minimum term
  • Our own servers in Germany, no US cloud
Create account →

Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.

Ask the agents about Pfizer

Analyst assessment of Pfizer

PRICE TARGET LOW

US$26.00

CONSENSUS

US$29.17

MEDIAN

US$29.00

PRICE TARGET HIGH

US$33.00

0

STRONG BUY

16

BUY

23

HOLD

1

SELL

0

STRONG SELL

40

TOTAL · Hold

As of: 09/10/2026

ANALYST FIRMRATINGACTIONDATE
JP MorganNeutralmaintain09/10/2026
Cantor FitzgeraldNeutralmaintain08/10/2026
ScotiabankSector Outperformmaintain06/10/2026
HSBCHoldmaintain10/09/2026
GuggenheimBuymaintain07/08/2026
GuggenheimBuymaintain13/07/2026
BMO CapitalOutperformmaintain13/07/2026
B of A SecuritiesNeutralmaintain10/07/2026

Pfizer stock metrics

P/E

39.09

P/B

1.98

EV/EBITDA

17.11

RETURN ON EQUITY

-0.3%

NET MARGIN

-1.6%

DEBT/EQUITY

0.74

DIVIDEND YIELD

5.8%

AS OF

28/06/2026

Free float & liquidity

FREE FLOAT

99.9%

FLOAT SHARES

5,692,036,026

AVG. DAILY VOLUME (30D)

31,670,310

Insider transactions (SEC)

ROLETRANSACTIONSHARESPRICEPLAN TYPEDATE

BOURLA ALBERT

OfficerPurchase38,00026.34Spontaneous12/08/2026

DAMICO JENNIFER B.

OfficerSale3,27825.4Spontaneous06/08/2026

Buckley Mortimer J

DirectorPurchase37,63225.52Spontaneous05/08/2026

BLAYLOCK RONALD E

DirectorPurchase39,23125.46Spontaneous05/08/2026

DAMICO JENNIFER B.

OfficerSale2,00025.7Spontaneous10/06/2026

Attention

1 mention today in US forums, 50% fewer than yesterdayPrice since yesterday: +0.5%

Forums (Reddit)

01/0926/0916/10

See the full forum history with Pro.

Institutional holders

FUND / INSTITUTIONSHARESCHANGEAS OF
Assenagon Asset Management S.A.7,514,902-4,387,47230/09/2026
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC4,132,122+973,54730/09/2026
Artemis Investment Management LLP3,761,718-3,850,87930/09/2026
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/2,077,952+16,16130/09/2026
FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND1,710,757-188,21430/09/2026
Page 1 / 3

Dividends & Stock splits

Dividends

EX-DATEPAY DATEAMOUNTYIELD
06/11/202607/12/2026US$0.435.8 %
24/07/202601/09/2026US$0.437 %
08/05/202612/06/2026US$0.436.7 %
23/01/202606/03/2026US$0.436.7 %
07/11/202501/12/2025US$0.437 %
Page 1 / 8

Stock splits

DATERATIO
17/11/2020527:500
01/07/19993:1
01/07/19972:1
03/07/19952:1
01/04/19912:1
Page 1 / 2

Smart Money

Register for free

Register now to see which funds are invested

  • 5 credits free on registration
  • Access to virtual portfolios and watchlist
  • No credit card, no payment details needed
  • No subscription, no minimum term
  • Our own servers in Germany, no US cloud
Create account →

Comparable stocks

Frequently asked questions about Pfizer stock

What does Pfizer do?

Pfizer Inc. is a company in the Healthcare sector, Drug Manufacturers - General industry, headquartered in United States.

The CEO is Albert Bourla, the company employs around 75,000 people.

The IPO was on 01/06/1972; the stock trades on NYSE under the ticker PFE.

What do analysts say about Pfizer stock?

40 analysts rate the stock, the consensus is Hold (as of 09/10/2026).

The average price target is US$29.17, ranging from US$26.00 to US$33.00, with a median of US$29.00.

This is an external assessment, not a statement by Market Jury.

When does Pfizer report next?

The next earnings date is 03/11/2026.

Around past earnings, price swings were roughly 24% stronger than usual.

Does Pfizer pay a dividend?

Yes. The last dividend was US$0.43 per share, ex-date 06/11/2026, paid on 07/12/2026.

The dividend yield is 5.8% (as of 28/06/2026).

Which stocks are comparable to Pfizer?

Comparable stocks include Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck &, Amgen, Gilead Sciences, Bristol-Myers Squibb Company and Biogen.

How can I get Pfizer stock analyzed?

Clicking "Analyze stock" lets five strategies assess Pfizer against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.

Not investment advice. Past performance is not an indicator of future results.